Purchase, N.Y. — December 1, 2025 — Cognition Therapeutics has unveiled its Phase 3 registrational plan for Zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference. The strategy follows alignment with the U.S. Food and Drug Administration (FDA) during a successful end-of-Phase 2 meeting, establishing a clear regulatory pathway for the company’s oral, once-daily small-molecule candidate. The program aims to enroll adults with mild-to-moderate Alzheimer’s disease, specifically enriched by lower plasma p-tau217 levels—a biomarker-driven approach supported by earlier clinical findings. Cognition is now preparing for further regulatory alignment with the European Medicines Agency (EMA) in February 2026.
Science Significance
The Phase 3 strategy is grounded in compelling evidence from the Phase 2 SHINE study, where participants with lower plasma p-tau217 levels demonstrated a 95% slowing of cognitive decline measured by ADAS-Cog11 when treated with Zervimesine compared with placebo. Zervimesine is designed to interrupt the toxic synaptic effects of Aβ and α-synuclein, two protein species central to Alzheimer’s and dementia with Lewy bodies (DLB). By targeting the sigma-2 receptor, Zervimesine acts through a pathway distinct from monoclonal antibodies, suggesting a potential to modulate both amyloid- and synuclein-driven dysfunction. The use of plasma p-tau217 as a screening biomarker enables precision enrichment, increasing the likelihood of detecting therapeutic benefit while optimizing trial efficiency. This biomarker-guided design reflects contemporary neurodegenerative science and represents a shift toward more individualized therapeutic strategies.
Regulatory Significance
During the FDA’s July 2025 end-of-Phase 2 meeting, regulators agreed that two six-month Phase 3 trials, each randomizing participants 1:1 to Zervimesine 100 mg or placebo, may be sufficient to support a future New Drug Application (NDA). Cognitive and functional outcomes will be assessed using the iADRS composite, a validated endpoint combining ADAS-Cog13 and ADCS-ADL. Participants completing either trial will be eligible for an open-label extension, enabling collection of long-term safety and durability data. Cognition will also conduct an EMA scientific advice meeting to ensure regulatory alignment across regions, an essential step for globally harmonized Alzheimer’s disease filings. Together, these actions signal a well-structured regulatory pathway, leveraging biomarker-based enrichment and validated endpoints consistent with modern FDA guidance for neuroscience drug development.
Business Significance
Advertisement
The Phase 3 roadmap positions Cognition Therapeutics for a major value-inflection point as it advances a clinically validated, non-biologic oral therapy into late-stage development. With monoclonal antibodies dominating the Alzheimer’s landscape, Zervimesine offers a differentiated mechanism that does not require infusion infrastructure, potentially broadening access and lowering healthcare delivery costs. The program’s biomarker-focused design may reduce trial size, development costs, and timelines—critical advantages for a clinical-stage company optimizing the allocation of capital across Alzheimer’s disease and DLB programs. Cognition is also evaluating resource deployment across multiple neurodegenerative indications, positioning Zervimesine as a potential franchise-level asset. The company’s success in securing major NIH funding—including an $81 million award for the START study—further strengthens its business footing as it advances toward registrational studies.
Patients’ Significance
For individuals living with Alzheimer’s disease, the advancement of Zervimesine represents meaningful progress toward a once-daily oral therapy that targets neuronal dysfunction without the risks associated with plaque-binding antibodies. The SHINE study’s data indicating substantial slowing of cognitive decline in biomarker-selected patients provides strong hope for a therapy capable of modifying the disease course. Leveraging plasma p-tau217 for patient selection may ensure that those most likely to benefit receive priority access during clinical evaluation. With Alzheimer’s disease causing relentless loss of memory, function, and independence, a safe and well-tolerated oral option could significantly improve quality of life for patients and caregivers. Zervimesine’s tolerability profile to date reinforces its potential suitability for broad patient populations.
Policy Significance
Zervimesine’s Phase 3 plan reflects emerging policy trends encouraging biomarker-driven trial designs, which improve efficiency while maintaining scientific rigor. As healthcare systems confront rising Alzheimer’s prevalence and cost, therapies that can be delivered orally and monitored through blood-based biomarkers align with policy priorities focused on lowering resource burdens and expanding equitable access. The program’s emphasis on FDA-validated endpoints and biomarkers may shape future Alzheimer’s clinical-trial standards, especially for small-molecule candidates. Alignment with both FDA and EMA ensures that the program is positioned within the global regulatory architecture, supporting future cross-market approval and reimbursement pathways.
Cognition Therapeutics’ presentation of its Phase 3 Zervimesine program at CTAD underscores the company’s momentum toward delivering a differentiated Alzheimer’s therapy built on biomarker-guided precision and a novel mechanism of action. With FDA alignment secured and EMA consultation forthcoming, the late-stage development pathway is clearer than ever. As Zervimesine advances toward pivotal studies, it stands as a compelling therapeutic candidate with the potential to reshape treatment strategies for Alzheimer’s disease and related neurodegenerative disorders.
Source: Cognition Therapeutics, Inc. press release
